Adjuvant therapy in renal cell carcinoma

Francesco Massari, Vincenzo Di Nunno, Chiara Ciccarese, Jeffrey Graham, Camillo Porta, Francesca Comito, Marta Cubelli, Roberto Iacovelli, Daniel Y.C. Heng

Research output: Contribution to journalReview articlepeer-review


Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.

Original languageEnglish
Pages (from-to)152-157
Number of pages6
JournalCancer Treatment Reviews
Publication statusPublished - Nov 1 2017


  • Adjuvant treatment
  • Clear cell renal cell carcinoma
  • Immunotherapy
  • Renal cell carcinoma
  • Tyrosine kinases inhibitors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Adjuvant therapy in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this